HomepageRARE • NASDAQ
add
Ultragenyx Pharmaceutical Inc
$Â 40,90
Na sluitingstijd:(0,00%)0,00
$Â 40,90
Gesloten: 10 mei, 16:01:46 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 41,22
Dag-range
$Â 40,26 - $Â 41,56
Jaar-range
$Â 31,52 - $Â 54,98
Beurswaarde
3,40Â mld. USD
Gem. volume
769,98K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 108,83Â mln. | 8,30% |
Bedrijfskosten | 98,70Â mln. | 4,15% |
Netto inkomsten | -170,68Â mln. | -4,09% |
Netto winstmarge | -156,83 | 3,88% |
Winst per aandeel | -2,03 | 12,70% |
EBITDA | -156,50Â mln. | -5,13% |
Effectief belastingtarief | -0,27% | — |
Balans
Totale activa
Totale passiva
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 412,08Â mln. | -34,52% |
Totale activa | 1,31Â mld. | -5,52% |
Totale passiva | 1,17Â mld. | 0,33% |
Totaal aandelenvermogen | 140,26 mln. | — |
Uitstaande aandelen | 83,07 mln. | — |
Koers-boekwaardeverhouding | 24,39 | — |
Rendement op activa | -29,55% | — |
Rendement op kapitaal | -36,22% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -170,68Â mln. | -4,09% |
Operationele kasstroom | -190,73Â mln. | -21,59% |
Kasstroom uit beleggingen | 94,44Â mln. | -15,16% |
Kasstroom uit financiering | -58,00K | 91,97% |
Nettomutatie in liquide middelen | -97,03Â mln. | -110,59% |
Vrije kasstroom | -158,09Â mln. | -12,26% |
Over
Ultragenyx is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. The company also has therapies approved outside the U.S. in Canada, Latin America, Europe, and Japan. Wikipedia
CEO
Opgericht
2010
Hoofdvestiging
Website
Werknemers
1.276